Moseley Annemarie
COO/EVP Clinical Development at BELLICUM PHARMACEUTICALS, INC
- Sold, on record
- $2.2M
- Dollars the filings state
- Form 4 sales
- 4
- Latest Dec 1, 2016
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- BELLICUM PHARMACEUTICALS, INCCOO/EVP Clinical Development
Sales by reason
0
Routine
0
Plan not stated
0
No plan
0
Unusual
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale BELLICUM PHARMACEUTICALS, INCUnusualJul 1, 2015 2015
Sold 35,000 shares at $20.62 ($722k)
Moseley Annemarie, COO/EVP Clinical Development
Sold 99.7% of holdings ($724k position)122 shares leftFirst sale on recordFiling
- 2 Form 4 sale BELLICUM PHARMACEUTICALS, INCUnusualJan 4, 2016 +187 days
Sold 35,000 shares at $19.07 ($668k)
Moseley Annemarie, COO/EVP Clinical Development
Sold 99.3% of holdings ($672k position)251 shares leftFiling
- 3 Form 4 sale BELLICUM PHARMACEUTICALS, INCUnusualJun 2, 2016 +150 days
Sold 25,000 shares at $13.00 ($325k)
Moseley Annemarie, COO/EVP Clinical Development
Sold 99% of holdings ($328k position)251 shares leftFiling
- 4 Form 4 sale BELLICUM PHARMACEUTICALS, INCUnusualDec 1, 2016 +182 days
Sold 25,000 shares at $17.54 ($438k)
Moseley Annemarie, COO/EVP Clinical Development
Sold 98.3% of holdings ($446k position)442 shares left0.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (4)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2016 | Dec 5, 2016 | BELLICUM PHARMACEUTICALS, INC | COO/EVP Clinical Development | Form 4 sale | 25,000 | $438k | 98.3% | Unusual | SEC |
| Jun 2, 2016 | Jun 6, 2016 | BELLICUM PHARMACEUTICALS, INC | COO/EVP Clinical Development | Form 4 sale | 25,000 | $325k | 99.0% | Unusual | SEC |
| Jan 4, 2016 | Jan 6, 2016 | BELLICUM PHARMACEUTICALS, INC | COO/EVP Clinical Development | Form 4 sale | 35,000 | $668k | 99.3% | Unusual | SEC |
| Jul 1, 2015 | Jul 6, 2015 | BELLICUM PHARMACEUTICALS, INC | COO/EVP Clinical Development | Form 4 sale | 35,000 | $722k | 99.7% | Unusual | SEC |